Orthotopic Tumor Model Development

Successful cancer drug development requires high-fidelity preclinical models for optimal therapy outcomes and successful translation into clinical use. While subcutaneous xenografts are easy to do, they neglect to integrate the complex biology and metastatic capabilities of human tumors. Here at Protheragen, we employ orthotopic tumor models to recapitulate native tumor behavior, invasiveness, therapeutic resistance, and metastatic spread, along with providing an appropriate physiologic milieu that mimics the native environment.

Overview of Orthotopic Tumor Models

Orthotopic tumor models are a highly specialized and increasingly essential tool in the field of oncology research. These models involve the transplantation of tumor cells into their original organ site within a host organism, thereby closely mimicking the natural biological environment and progression of human cancers. Unlike xenograft models that place tumors in ectopic sites, orthotopic models provide a more accurate representation of the tumor's interaction with the host's immune system, vasculature, and surrounding tissue. This fidelity is crucial for understanding the complex mechanisms of cancer growth, metastasis, and response to therapeutic interventions.

Fig.1 The occurrence of primary and metastatic tumors in gastric cancer orthotopic PDXs. (Kang W., et al., 2021)

Applications of Orthotopic Models in Therapeutics Development

Orthotopic models are used across the drug discovery pipeline:

• Target Validation: Demonstrating that inhibiting a pathway alters tumor behavior in the correct anatomical site.
• Lead Optimization: Refining drug properties to ensure efficacy within complex TMEs.
• Biomarker Discovery: Identifying molecular signatures that predict response in patient-matched models.
• Resistance Mechanism Elucidation: Understanding intrinsic and acquired resistance under TME pressure.

These models also serve as platforms for nanoparticle-based delivery systems, allowing real-time tracking of drug biodistribution and release in orthotopic settings.

Table 1. Examples of human xenograft and mouse syngeneic orthotopic tumor models. (Stribbling S. M., et al., 2024)

Our Services

At Protheragen, orthotopic tumor modeling isn't merely a service offered—they are a tremendous asset to drug developers who require biological fidelity, predictive accuracy, and regulatory-grade data. Ensuring innovation, customization, and scientific rigor, Protheragen's partners are empowered to advance the development of transformative cancer therapies and decrease pipeline attrition.

Types of Orthotopic Tumor Models

• Tumor Cell Line-Derived Orthotopic Models (CDX): Fast implementation using established cell lines, ideal for early-stage screening.
• Patient-Derived Orthotopic Xenografts (PDOX): Directly implanted surgical specimens maintain native tumor architecture, stroma, and biomarker expression.
• Organoid-Based Orthotopic Models: Miniaturized patient tumors cultured in vitro and orthotopically implanted for scalable, reproducible testing.

Optional Disease Models

Protheragen's model is designed with client-specific needs in mind—whether the goal is lead compound prioritization, mechanistic studies, or immunotherapy testing. Parameters like cell source, mouse strain, imaging frequency, and therapeutic regimen are all configurable. If you are interested in our services, please feel free to contact us.

References

• Kang, Wonyoung, et al. "Development of a novel orthotopic gastric cancer mouse model." Biological procedures online 23.1 (2021): 1.
• Stribbling, Stephen M., Callum Beach, and Anderson J. Ryan. "Orthotopic and metastatic tumour models in preclinical cancer research." Pharmacology & Therapeutics 257 (2024): 108631.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.